Thus, therapies aimed at decreasing GRP78 levels, which result in the inhibition of tumor cell proliferation and resensitization of tumor cells to chemotherapeutic drugs, may hold promise for cancer treatment. This evidence concerns the gene HSPA5 and neoplasm.